EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program

David T Rubin, Charlie W Lees, Filip Baert, Maria Kudela, Abhishek Bhattacharjee, Krisztina Lazin, Martina Goetsch, Arcangelo M Abbatemarco, Karolina Wosik, John K Marshall

Therapeutic Advances in Gastroenterology · 2026-07 · 19

DOI: 10.1177/17562848261470909 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Gastroenterology, online erschienen am 27.07.2026. Verfasst von David T Rubin und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many patients show inadequate response or intolerance to conventional therapies for ulcerative colitis (UC), including 5-aminosalicylates (5-ASA), thiopurines, and corticosteroids (CS). Etrasimod is an oral, once daily (QD), selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of UC.

Objectives

We assessed efficacy and safety as a first-line advanced therapy following different scenarios of conventional treatment.

Design

In the phase III, multicenter, double-blind, placebo-controlled ELEVATE UC trials, eligible patients were randomized 2:1 to etrasimod 2 mg QD or placebo.

Methods

Subgroups of patients post-5-ASA failure (prespecified), post-5-ASA/CS (post hoc), and post-thiopurine/5-ASA/CS (post hoc) were assessed for clinical, endoscopic, and histologic endpoints. Safety was assessed throughout the trials.

Results

In ELEVATE UC 52, 74 patients (45 receiving etrasimod 2 mg QD and 29 receiving placebo) had prior failure of 5-ASA only. Among these patients, a greater proportion of those treated with etrasimod versus placebo met clinical, endoscopic, and histologic endpoints at week 12 and week 52 (all p < 0.01). In complementary analyses using data pooled from ELEVATE UC 52 and ELEVATE UC 12, among those exposed to 5-ASA/CS ( N = 197), a greater proportion receiving etrasimod versus placebo met all clinical efficacy endpoints assessed at week 12 and week 52 (all p < 0.001). In those exposed to thiopurine/5-ASA/CS ( N = 104), similar efficacy was observed with statistically significant differences at week 12 and numerical differences that did not reach statistical significance at week 52. Subgroup safety outcomes were similar to those in the overall population.

Conclusion

Etrasimod is an effective first-line advanced treatment option for patients with UC early in their treatment journey, after 5-ASA, thiopurine, or CS use.

Trial registration

ClinicalTrials.gov: NCT03945188, NCT03996369.

Schlagwörter

Stichwörter der Autor:innen

advanced therapyetrasimodulcerative colitis

Autor:innen und Institutionen

  • University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA.
  • Institute of Genetics & Molecular Medicine, The University of Edinburgh, Edinburgh, UK.
  • Edinburgh IBD Unit, Western General Hospital, NHS Lothian, Edinburgh, UK.
  • Department of Gastroenterology, AZ Delta, Roeselare, Belgium.
  • Pfizer Inc., Cambridge, MA, USA.
  • Pfizer Healthcare India Private Ltd., Chennai, India.

Förderung

  • Pfizer Inc

Zitieren

APA

Rubin, D. T., Lees, C. W., Baert, F., Kudela, M., Bhattacharjee, A., Lazin, K., Goetsch, M., Abbatemarco, A. M., Wosik, K., & Marshall, J. K. (2026). The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program. Therapeutic Advances in Gastroenterology, 19. https://doi.org/10.1177/17562848261470909

Vancouver

Rubin DT, Lees CW, Baert F, Kudela M, Bhattacharjee A, Lazin K, et al. The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program. Therapeutic Advances in Gastroenterology. 2026;19. doi:10.1177/17562848261470909

BibTeX
@article{Rubin2026,
  author = {Rubin, David T and Lees, Charlie W and Baert, Filip and Kudela, Maria and Bhattacharjee, Abhishek and Lazin, Krisztina and Goetsch, Martina and Abbatemarco, Arcangelo M and Wosik, Karolina and Marshall, John K},
  title = {The efficacy and safety of etrasimod as a first-line advanced therapy for ulcerative colitis: prespecified and post hoc subgroup data from the ELEVATE UC clinical program},
  journal = {Therapeutic Advances in Gastroenterology},
  year = {2026},
  volume = {19},
  doi = {10.1177/17562848261470909}
}
Kostenlos starten →